on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics to Host Webcast on Lusvertikimab for Inflammatory Bowel Diseases
OSE Immunotherapeutics announced a forthcoming webcast on September 2, 2026. The session will focus on their flagship product, lusvertikimab, which is employed in Inflammatory Bowel Diseases treatment. Key opinions from respected clinicians will highlight insights into IL-7R biology and promising findings from the CoTiKis Phase 2 study on Ulcerative Colitis.
The webcast will also discuss prospective development plans targeting Chronic Pouchitis. Notable participants include Dr. Laurent Peyrin-Biroulet from Nancy University Hospital and Dr. Maia Kayal from the Icahn School of Medicine, alongside OSE's CEO Marc Le Bozec and Chief Scientific Officer Aurore Morello.
Scheduled for noon ET (6pm CET), the webcast will be live in English with optional French subtitles. Interested parties can access the event through the provided online link.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news